Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | EIF4E | P06730 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231457 | 0.86 | KMT2A (0.72) | KMT2ATDP1ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL11229565 | 0.85 | TDP1 (0.57) | KMT2ATDP1ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL8447120 | 0.85 | KMT2A (0.70) | KMT2ATDP1ALDH1A1CYP3A4ALOX15 | |
| Hydrochloric Acid SCHEMBL6222540 | 0.85 | KMT2A (0.70) | KMT2ATDP1ALDH1A1CYP3A4ALOX15 | |
| Potassium Ion SCHEMBL11056843 | 0.85 | KMT2A (0.70) | KMT2ATDP1ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL11054244 | 0.85 | KMT2A (0.70) | KMT2ATDP1ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL2770320 | 0.82 | TSHR (0.68) | KMT2AALDH1A1XDHCASP1SMN1; SMN2 | |
| SCHEMBL6850686 | 0.82 | HNF4A (0.64) | KMT2ATDP1ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL1761462 | 0.82 | TDP1 (0.54) | KMT2ATDP1MAPK1POLBSMN1; SMN2 | |
| SCHEMBL1761421 | 0.81 | TDP1 (0.53) | KMT2ATDP1ALDH1A1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118302-A1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118302-A1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118302-A1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| EP-1805156-B1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-1805156-B1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-12-22 | — | — | EP | disclosed |
| US-7759376-B2 | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759376-B2 | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759376-B2 | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2010-07-20 | — | — | US | disclosed |
| EP-1805156-A4 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORP (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20070265298-A1 | Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265298-A1 | Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265298-A1 | Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1805156-A2 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006044775-A2 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265298-A1 | Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity | FABP4, GPR119, PGC | KMT2A 249/4885TDP1 4638/4885ALDH1A1 93/4885 |
| US-20110118302-A1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, PGC | KMT2A 249/4885TDP1 4638/4885ALDH1A1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.